Study | Nurses’ role | Population diagnosis | Outcome | Measurement method/scale | FUP, months | Nurse group | Physician group | Effect estimate | |||
---|---|---|---|---|---|---|---|---|---|---|---|
First author, y | Location | ||||||||||
Binary data | n | N | n | N | RR (95 % CI) | ||||||
Heart disease | |||||||||||
Andryukhin et al., 2011 [18] | RU 1 | NP/LN | Heart failure PEF | Positiveb changes in class HF | NYHA | 6 | 18 | 40 | 8 | 35 | 1.97 (0.98 to 3.96) |
UK 1 | NP | CHD secondary prevention | Chest pain | ATyPeS/SF36a | 12 | 232 | 508 | 250 | 498 | 0.91 (0.80 to 1.04) | |
UK 1 | NP | CHD secondary prevention | Chest pain | ATyPeS/SF36 | 48 | 147 | 430 | 129 | 385 | 1.02 (0.84 to 1.24) | |
UK 1 | NP | CHD secondary prevention | Worsening chest pain | ATyPeS/SF36 | 12 | 37 | 519 | 54 | 500 | 0.66 (0.44 to 0.98) | |
UK 1 | NP | CHD secondary prevention | Worsening chest pain | ATyPeS/SF36 | 48 | 44 | 439 | 35 | 395 | 1.13 (0.74 to 1.73) | |
Lung disease | |||||||||||
Hesselink et al., 2004 [26] | NL 1 | LN | Asthma/COPD | No chronic cough and phlegm production or an improvement | Present/absent | 12 | 43 | 108 | 39 | 85 | 0.87 (0.63 to 1.20) |
Hesselink et al., 2004 [26] | NL 1 | LN | Asthma/COPD | No chronic cough and phlegm production or an improvement | Present/absent | 24 | 41 | 93 | 33 | 79 | 1.06 (0.75 to 1.49) |
Hesselink et al., 2004 [26] | NL 1 | LN | Asthma/COPD | No wheezing or an improvement in frequency | Never, ever, most days and night | 12 | 68 | 106 | 51 | 85 | 1.07 (0.85 to 1.34) |
Hesselink et al., 2004 [26] | NL 1 | LN | Asthma/COPD | No wheezing or an improvement in frequency | Never, ever, most days and night | 24 | 53 | 93 | 37 | 79 | 1.22 (0.91 to 1.63) |
Infectious disease | |||||||||||
Fairall et al., 2012 [25] | ZA 2 | LN | HIV/AIDS | Suppressed viral load in patients receiving ARTd | Viral load | 12–18 | 2156 | 3029 | 2230 | 3202 | 1.02 (0.99 to 1.06) |
Fairall et al., 2012 [25] | ZA 1 | LN | HIV/AIDS | Suppressed viral load in patients starting ARTd | Viral load | 12–18 | 1706 | 2375 | 1062 | 1449 | 0.98 (0.94 to 1.02) |
Diverse, acute and minor conditions | |||||||||||
Shum et al., 2000 [32] | UK 2 | NP | Acute and minor | Same, improved or cured self-reported health status | Murphy | 0.5 | 650 | 672 | 646 | 661 | 0.99 (0.97 to 1.01) |
Kinnersley et al., 2000 [34] | UK 3 | NP | Diverse conditions | Same or improved symptoms (much better, better or unchanged) | Likert-type and single reminders | 0.5 | 472 | 484 | 515 | 529 | 1.00 (0.98 to 1.02) |
Continuous data | Mean (SD) | N | Mean (SD) | N | WMD (95 % CI) | ||||||
Lung disease | |||||||||||
Hesselink et al., 2004 [26] | NL 1 | LN | Asthma/COPD | Mean change score in dyspnea | MRCQTc | 12 | 0.00 (1.3) | 115 | 0.10 (1.3) | 94 | −0.10 (−0.45 to 0.25) |
Hesselink et al., 2004 [26] | NL 1 | LN | Asthma/COPD | Mean change score in dyspnea | MRCQTc | 24 | 0.20 (1.4) | 96 | 0.30 (1.3) | 80 | −0.10 (−0.50 to 0.30) |
Metabolic disease | |||||||||||
Denver et al., 2003 [23] | UK 5 | NP+ | DM2 with hypertension, under BPLT | Mean fall in 10-year CHD risk | Framingham CHD risk score | 6 | −2.33 (3.87) | 59 | −0.33 (2.16) | 56 | −2.00 (−3.14 to −0.86) |
Denver et al., 2003 [23] | UK 5 | NP+ | DM2 with hypertension, under BPLT | Mean fall in 10-year stroke risk | Framingham stroke risk score | 6 | −4.33 (6.0) | 59 | −1.80 (3.53) | 56 | −2.53 (−4.32 to −0.74) |
Digestive disease | |||||||||||
Chan et al., 2009 [22] | UK 6 | NP+ | GORD, moderate gastritis | Mean score, dyspepsia severity | GDSS (Gladys) scoreg | 6 | 4.90 (2.9) | 89 | 7.20 (3.1) | 86 | −2.30 (−3.19 to −1.41) |
Skin disease | |||||||||||
Kernick et al., 2000 [28] | UK 4 | NP+ | Psoriasis/eczema | Mean score for symptoms and severity of skin condition | Self-evaluation clinical scoree | 4 | 7.60 (3.3) | 35 | 8.1 (3.3) | 46 | −0.50 (−1.95 to 0.95) |
Common complaints | |||||||||||
Dierick-van Daele et al., 2009 [24] | NL 2 | NP+ | Common complaints | Mean difference in the degree of burden of illness | LikertQTf | 0.5 | −1.77 (3.18) | 473 | −1.50 (2.63) | 451 | −0.27 (−0.65 to 0.11) |
Dierick-van Daele et al., 2009 [24] | NL 2 | NP+ | Common complaints | Mean difference in the concerns about illness | LikertQTf | 0.5 | −1.51 (3.20) | 476 | −1.40 (2.97) | 450 | −0.11 (−0.51 to 0.29) |
Qualitative data | |||||||||||
Metabolic disease | |||||||||||
Houweling et al., 2011 [27] | NL 3 | NP | DM2 | Perceived burden of DM symptoms and rating of symptom troublesomeness | Type 2 Diabetes Symptom Checklisth | 14 | “significant differences at follow-up for some of the Diabetes Symptom Score dimensions (data not shown). After 14 months, the mean sub-dimension scores for DM symptoms ‘fatigue’ and ‘cognitive distress’ and the total scores were lower in each group, although no difference was observed between the groups.” | ||||
Lung disease | |||||||||||
Hesselink et al., 2004 [26] | NL 1 | LN | Asthma/COPD | Respiratory complaints within two weeks after intervention | Disturbance (present/absent) for >1 day or night | 0.5 | “no significant group differences in the number of days or nights disturbed, OR 0.96 (95 % CI 0.56 to 1.61)” | ||||
Common complaints | |||||||||||
Dierick-van Daele et al., 2009 [24] | NL 2 | NP+ | Common complaints | Complications due to illness | Mean number of days of work absence | 0.5 | “1.11 days (nurse, SD 0.32; physician, SD 0.31) of work absence in average” | ||||
Dierick-van Daele et al., 2009 [24] | NL 2 | NP+ | Common complaints | Complications due illness | Mean number of days of inability for daily activities | 0.5 | “no statistically significant differences between groups; mean days unable for daily activities: nurse-led care 2.53 (SD 2.89), physician-led care 2.69 (SD 2.90)” |